Celleron Therapeoutics

Celleron Therapeutics is an oncology company focused on the clinical development of novel therapies for treating cancer. Celleron's vision is that the future of cancer treatment lies in the ability to match therapeutic approaches with individual patients. Celleron’s preclinical research pipeline consists of a series of target enzymes involved in epigenetic control, which play a key role in cancer biology. They have been selected using a systems biology approach to increase the likelihood of biochemical synergy when they enter clinical trials. Celleron’s proprietary drug CXD101 is a dual-mechanism HDAC inhibitor with multiple characteristics that distinguish it from competing compounds. CXD101 is a novel epigenetic immunomodulator with the ability to enhance immune recognition of tumor cells.